share_log

NexImmune | NT 10-K: Others

NexImmune | NT 10-K: Others

NexImmune | NT 10-K:其他
美股SEC公告 ·  03/29 16:09
Moomoo AI 已提取核心信息
NexImmune, Inc. has filed a Notification of Late Filing with the SEC, indicating that its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, will be delayed. The company attributes the delay to a significant reduction in workforce, which has left it with fewer resources to prepare and review the financial statements. Despite the reduction, key management and scientific team members remain to support ongoing business efforts. NexImmune expects to file the Form 10-K within the fifteen-day extension period allowed under Rule 12b-25 of the Securities Exchange Act. The company has also included forward-looking statements in the notification, cautioning that actual results may differ from current expectations due to risks and uncertainties. The notification was signed by CEO Kristi Jones on March 29, 2024.
NexImmune, Inc. has filed a Notification of Late Filing with the SEC, indicating that its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, will be delayed. The company attributes the delay to a significant reduction in workforce, which has left it with fewer resources to prepare and review the financial statements. Despite the reduction, key management and scientific team members remain to support ongoing business efforts. NexImmune expects to file the Form 10-K within the fifteen-day extension period allowed under Rule 12b-25 of the Securities Exchange Act. The company has also included forward-looking statements in the notification, cautioning that actual results may differ from current expectations due to risks and uncertainties. The notification was signed by CEO Kristi Jones on March 29, 2024.
NexImmune, Inc.已向美国证券交易委员会提交了逾期申报通知,表示其截至2023年12月31日财年的10-K表年度报告将被推迟。该公司将延迟归因于员工人数的大幅裁员,这使其编制和审查财务报表的资源减少了。尽管有所减少,但主要管理层和科学团队成员仍在支持正在进行的业务工作。NexImmune预计将在《证券交易法》第12b-25条允许的十五天延期内提交10-K表格。该公司还在通知中加入了前瞻性陈述,警告说,由于风险和不确定性,实际业绩可能与当前的预期有所不同。该通知由首席执行官克里斯蒂·琼斯于2024年3月29日签署。
NexImmune, Inc.已向美国证券交易委员会提交了逾期申报通知,表示其截至2023年12月31日财年的10-K表年度报告将被推迟。该公司将延迟归因于员工人数的大幅裁员,这使其编制和审查财务报表的资源减少了。尽管有所减少,但主要管理层和科学团队成员仍在支持正在进行的业务工作。NexImmune预计将在《证券交易法》第12b-25条允许的十五天延期内提交10-K表格。该公司还在通知中加入了前瞻性陈述,警告说,由于风险和不确定性,实际业绩可能与当前的预期有所不同。该通知由首席执行官克里斯蒂·琼斯于2024年3月29日签署。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息